Extended Data Fig. 10: IL-2(V) does not synergize with PD-1 blockade during chronic LCMV infection.
From: PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
LCMV chronically infected mice were left untreated, or treated with anti-PD-L1 antibody, anti-PD-L1 plus IL-2 wild-type (IL-2(WT)), or anti-PD-L1 plus IL-2(V) (modified IL-2 with abolished CD25 binding) for 2 weeks. a, Numbers of DbGP276+ CD8+ T cells in the indicated tissues of the four groups of mice. b, Numbers of DbGP33+ and DbGP276+ CD8+ T cells in blood (per 1x 106 PBMCs) in the four groups. c, Numbers of IFNγ+ CD8+ T cells in the different groups. Spleen cells were stimulated with pools of LCMV-specific peptides for 5 h and analysed by intracellular cytokine staining. d, Summary data for the expression of various phenotypic markers on DbGP33+ and DbGP276+ CD8+ T cells after the different treatments. Results were pooled from 2-3 experiments with 2-3 mice per group in each experiment. Data are presented as geometric mean and 95% CI (a–c) or mean and SD (d) with p values. Statistical comparisons were performed using Kruskal-Wallis test with Dunn’s multiple-comparison test (a–c) or one-way ANOVA with Tukey’s multiple-comparison test (d). Untx, untreated.
